PARP inhibitors have been approved for the treatment of ovarian cancer, HER2-negative breast cancer, pancreatic ductal adenocarcinoma (PDAC) and metastatic castration-resistant prostate cancer (mCRPC) (Table 1). The gene discussed is PARP1; the disease is ovarian cancer.